Geron (NASDAQ:GERN) Share Price Passes Above 200 Day Moving Average – What’s Next?

Geron Corporation (NASDAQ:GERN) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.38 and traded as high as $1.43. Geron shares last traded at $1.41, with a volume of 16,679,509 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GERN. UBS Group reissued a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. TD Cowen reiterated a “buy” rating on shares of Geron in a research note on Thursday, January 29th. HC Wainwright reissued a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a research report on Wednesday, January 28th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Geron has an average rating of “Hold” and a consensus price target of $2.17.

Geron Stock Performance

The firm has a market capitalization of $903.16 million, a PE ratio of -10.85 and a beta of 0.58. The company has a debt-to-equity ratio of 0.53, a current ratio of 4.66 and a quick ratio of 3.62. The company’s fifty day simple moving average is $1.56 and its 200 day simple moving average is $1.38.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.02). Geron had a negative return on equity of 28.86% and a negative net margin of 46.65%.The business had revenue of $48.02 million during the quarter, compared to analysts’ expectations of $50.43 million. As a group, equities research analysts expect that Geron Corporation will post -0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Geron

Several institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Geron by 2.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock worth $627,000 after acquiring an additional 8,123 shares during the period. E Fund Management Co. Ltd. raised its stake in shares of Geron by 12.0% during the 2nd quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 9,849 shares during the period. LCM Capital Management Inc raised its stake in shares of Geron by 80.6% during the 4th quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 10,000 shares during the period. Velan Capital Investment Management LP lifted its holdings in Geron by 14.3% during the 3rd quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Swiss Life Asset Management Ltd lifted its holdings in Geron by 73.6% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 11,182 shares in the last quarter. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.